Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM.
Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).
Company Details
- Employees
- 18
- Founded
- 2019
- Address
- 26, Beobwon-Ro 9-Gil, H Business Park,d-Dong 1011-Ho,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.prazertx.com
- HQ
- Seoul
Prazer Therapeutics Questions
Prazer Therapeutics's website is http://www.prazertx.com
Prazer Therapeutics's LinkedIn profile is https://kr.linkedin.com/company/prazertx
Prazer Therapeutics has
18 employees.
View email and phone details for 18
employees at Prazer Therapeutics.
Prazer Therapeutics's industry is
Biotechnology Research
Prazer Therapeutics's top competitors are
Sanofi,
Meresga,
Spark Biopharma, Inc.,
Merck Kgaa, Darmstadt, Germany,
Springworks Therapeutics,
Neuramedy,
Avistone Biotechnology Co., Inc,
Veeva Systems,
Costa Blanca Wellness Festival,
Nurix Therapeutics.
Prazer Therapeutics's categories are Biotechnology Research
Prazer Therapeutics's founding year is 2019
